Kang Ho Suk, Kim Joo-Hee, Kim Ji Hee, Bang Woo Jin, Yoo Dae Myoung, Lee Na-Eun, Han Kyeong Min, Kim Nan Young, Choi Hyo Geun, Min Kyueng-Whan, Kwon Mi Jung
Division of Gastroenterology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea.
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea.
Pharmaceuticals (Basel). 2024 Aug 10;17(8):1056. doi: 10.3390/ph17081056.
Despite growing interest in the preventive effects of statins, as lipid-lowering agents, on migraine attacks, comprehensive nationwide studies comparing migraine likelihood between statin users and controls are lacking. Our nested case-control study within the Korean National Health Insurance Service-Health Screening Cohort (2002-2019) investigated this association using 38,957 migraine patients and 155,828 controls, considering migraine subtypes (with/without aura) and statin types (lipophilic vs. hydrophilic). Using propensity score matching and adjusting for confounders, statin use was linked to reduced migraine likelihood overall (odds ratio (OR) 0.93), particularly for migraines with aura (OR 0.75) and without aura (OR 0.94). Lipophilic statins were effective for both subtypes, while hydrophilic statins mainly reduced the likelihood of migraines without aura. Subgroup analyses showed consistent benefits across demographics, but varied effectiveness based on weight, smoking, alcohol use, hemoglobin levels, and dyslipidemia history. In summary, this nationwide cohort study suggests that statin use may reduce migraine likelihood among Korean adults across diverse demographics and clinical profiles, but varied effectiveness based on certain lifestyle and comorbidity factors underscores the importance of considering individual patient profiles when assessing the potential benefits of statin therapy for migraine prevention.
尽管他汀类药物作为降脂药对偏头痛发作的预防作用越来越受到关注,但目前缺乏在全国范围内比较他汀类药物使用者和对照组偏头痛发生可能性的综合性研究。我们在韩国国民健康保险服务健康筛查队列(2002 - 2019年)中进行的巢式病例对照研究,使用了38957例偏头痛患者和155828例对照,考虑了偏头痛亚型(有无先兆)和他汀类药物类型(亲脂性与亲水性),对这种关联进行了调查。通过倾向评分匹配和对混杂因素进行调整,使用他汀类药物总体上与偏头痛发生可能性降低相关(比值比(OR)为0.93),特别是对于有先兆偏头痛(OR为0.75)和无先兆偏头痛(OR为0.94)。亲脂性他汀类药物对两种亚型均有效,而亲水性他汀类药物主要降低无先兆偏头痛的发生可能性。亚组分析显示,在不同人口统计学特征中均有一致的益处,但根据体重、吸烟、饮酒、血红蛋白水平和血脂异常病史,其有效性有所不同。总之,这项全国性队列研究表明,使用他汀类药物可能会降低不同人口统计学特征和临床特征的韩国成年人偏头痛的发生可能性,但基于某些生活方式和合并症因素的不同有效性强调了在评估他汀类药物预防偏头痛潜在益处时考虑个体患者特征的重要性。